Anticoagulants: prevent or treat thrombosis while actively managing bleeding risk
Anticoagulants reduce formation and extension of fibrin-rich clots; they do not “dissolve” an established clot. Their benefit can be lifesaving in venous thromboembolism (VTE), atrial fibrillation and selected cardiac/prosthetic-valve settings, but every prescription must balance thrombosis risk against bleeding risk, renal function, drug interactions, pregnancy status and planned procedures.
Safety first
Major bleeding, haemodynamic instability, suspected intracranial bleeding, spinal/epidural haematoma, or urgent surgery requires emergency assessment and protocol-led reversal. Do not improvise anticoagulant doses, bridging or reversal from a summary page.
1. Haemostasis and where the drugs act
| Stage | Key event | Drug relevance |
|---|---|---|
| Primary haemostasis | Platelet adhesion/aggregation creates initial plug | Mainly targeted by antiplatelet drugs, not the focus here. |
| Secondary haemostasis | Coagulation cascade generates thrombin; thrombin turns fibrinogen into fibrin | Heparins, warfarin and DOACs reduce thrombin or factor Xa activity. |
| Fibrinolysis | Plasmin breaks down fibrin | Thrombolytics act here; anticoagulants prevent clot propagation rather than lyse clot. |
2. Core classification
Unfractionated heparin (UFH)
Parenteral indirect anticoagulant. Potentiates antithrombin, inhibiting IIa (thrombin) and Xa. Rapid onset/offset; adjustable infusion; monitored with aPTT or anti-Xa per protocol.
Low-molecular-weight heparin (LMWH)
Enoxaparin, dalteparin. More anti-Xa than anti-IIa activity, predictable SC effect and usually no routine laboratory monitoring. Renal function and body weight matter.
Vitamin-K antagonist
Warfarin inhibits vitamin-K recycling, reducing synthesis of II, VII, IX and X and proteins C/S. Delayed onset; requires INR monitoring and has many interactions.
DOACs
Apixaban/rivaroxaban/edoxaban inhibit factor Xa; dabigatran directly inhibits thrombin. Fixed-dose regimens are common, but renal function, indication and interactions still determine suitability.
3. Indications: ask “which clot, which patient, which duration?”
- Treatment and secondary prevention of DVT and pulmonary embolism.
- Prevention of embolic stroke in eligible atrial fibrillation.
- Mechanical heart valves and selected valvular disease—warfarin remains important; DOAC suitability must be checked carefully.
- Perioperative, hospital or obstetric thromboprophylaxis in selected high-risk patients.
- Acute coronary and procedural settings with specialist protocols.
Anticoagulant choice is indication-specific. A drug appropriate for non-valvular AF may be wrong for mechanical valves, severe renal impairment, pregnancy or antiphospholipid syndrome. “Blood thinner” is not an adequate prescription category.
4. Mechanism, onset and monitoring table
| Group | Main target | Onset/monitor | Important practical point |
|---|---|---|---|
| UFH | Antithrombin → IIa and Xa | Immediate IV; aPTT/anti-Xa according to protocol | Preferred in some unstable, high-bleeding-risk or rapidly reversible situations; monitor platelets for HIT. |
| LMWH | Antithrombin → Xa > IIa | SC; routine anti-Xa not usually needed | Adjust/avoid according to renal function and indication; weight-based treatment dosing is common. |
| Warfarin | Vitamin-K epoxide reductase | Delayed; PT/INR | Early protein-C reduction can create transient hypercoagulability; some acute indications need heparin overlap. |
| Factor-Xa DOACs | Xa | Rapid oral effect; no routine INR | Assess renal/hepatic function, adherence and interacting P-gp/CYP3A4 medicines. |
| Dabigatran | Direct thrombin (IIa) | Rapid oral effect; no routine INR | Renal clearance is important; check product instructions and local protocol. |
5. Before starting: the anticoagulation safety checklist
- Confirm the indication, intended dose and duration; distinguish prophylaxis from treatment.
- Document weight, age, pregnancy possibility, renal function, liver disease, previous bleeding, falls risk, alcohol use and adherence ability.
- Baseline tests as relevant: FBC/platelets, creatinine/eGFR, liver tests, PT/INR/aPTT; pregnancy testing where clinically appropriate.
- Review every medicine: NSAIDs, aspirin/antiplatelets, SSRIs, antibiotics/antifungals, antiepileptics, herbal products and other anticoagulants.
- Ask about planned dental, surgical, spinal/epidural or invasive procedures before the first dose.
6. Warfarin: the exam and ward essential
Warfarin’s effect is measured by INR. For many indications the target is 2.0–3.0, but targets differ (for example, certain mechanical valves), so use the documented indication-specific range. Dose changes must be guided by a monitored protocol. Warfarin interacts with many medicines and with inconsistent vitamin-K intake. Counsel a consistent dietary pattern rather than telling patients to avoid all green vegetables.
Warfarin counselling
- Take at the same time each day; never double a missed dose without advice.
- Attend INR tests and carry anticoagulant identification.
- Tell every clinician/dentist/pharmacist before new medicines or procedures.
- Report bleeding, pregnancy, illness with poor intake/diarrhoea, or major diet/alcohol change.
7. Heparin and HIT
Heparin-induced thrombocytopenia (HIT) is an immune, prothrombotic complication—platelets fall but thrombosis risk rises. Suspect it with a significant platelet fall or new thrombosis after heparin exposure. Stop all heparin and obtain urgent senior/specialist guidance; do not simply “give platelets” or switch casually to LMWH because cross-reactivity may occur.
UFH is reversed with protamine. Protamine partly reverses LMWH; follow the local emergency protocol.
8. DOACs: simple dosing does not mean zero monitoring
DOACs have predictable pharmacokinetics and do not need routine INR testing, but patients still need periodic renal function, liver function, FBC, adherence and interaction review. Their anticoagulant effect can decline within about 12–24 hours after the last dose, so missed doses matter. Do not use INR to measure their activity or use a normal INR as proof that there is no clinically important DOAC effect.
Procedure and neuraxial safety
Timing of interruption/restart depends on the drug, renal function, bleeding risk and procedure. Spinal/epidural procedures carry a rare but devastating haematoma risk. Liaise with anaesthesia/surgery and follow the local peri-procedural anticoagulation protocol.
9. Bleeding: immediate structured response
| Step | Action |
|---|---|
| 1. Stabilise | ABC assessment, haemodynamics, IV access, blood group/crossmatch and resuscitation as needed. |
| 2. Identify drug/timing | Name, last dose, indication, renal function, co-medications and any overdose. |
| 3. Stop contributing agents | Withhold anticoagulant; review antiplatelets/NSAIDs and local haemostatic measures. |
| 4. Laboratory/imaging | FBC, renal/liver function, coagulation tests; targeted DOAC assays if available; urgent CT when intracranial bleeding suspected. |
| 5. Reverse protocol-led | Warfarin: vitamin K plus PCC for major bleeding in many protocols. Dabigatran: idarucizumab where available. Xa inhibitors: andexanet alfa or PCC according to local availability/protocol. |
Never delay emergency referral while searching for a perfect reversal agent. Reversal is reserved for life-threatening/uncontrolled major bleeding or truly urgent procedures and must weigh thrombosis risk.
10. Red flags patients must know
- Vomiting blood/coffee-ground material, black tarry stool, rectal bleeding or heavy unexplained vaginal bleeding.
- Red/brown urine, severe persistent headache, collapse, new weakness/speech change, head injury or severe back pain with leg weakness after spinal procedures.
- Large unexplained bruises, prolonged nosebleed, breathlessness, chest pain, swollen painful leg, or missed doses with new VTE symptoms.
11. Case application
Case 1 — AF with CKD
Before selecting an anticoagulant, confirm stroke/bleeding assessment, eGFR trend, age/weight, drug interactions and whether valve disease changes suitability. Renal function determines dose eligibility and review interval.
Case 2 — warfarin plus antibiotics
A patient on warfarin starts an antibiotic and reports easy bruising. Check INR promptly and review interacting medicines; do not advise arbitrary self-dose changes.
Case 3 — suspected major bleed
A patient on apixaban has melena, dizziness and hypotension. Treat as emergency: resuscitate, withhold anticoagulant, establish timing/renal function and activate the major-bleeding protocol.
12. High-yield summary
- Anticoagulants prevent/limit clot formation; thrombolytics lyse fibrin clots.
- UFH: aPTT/anti-Xa monitoring and protamine reversal; LMWH: predictable anti-Xa-predominant effect.
- Warfarin requires INR; vitamin-K intake should be consistent, not eliminated.
- DOACs require no routine INR but require renal function, adherence and interaction review.
- HIT is thrombocytopenia with thrombosis risk.
- Major bleeding is an emergency; use a drug-specific, local reversal pathway.
13. Further study and sources
- Course reference: Anticoagulants teaching presentation.
- NICE/BNF: Oral anticoagulants.
- MedlinePlus: Warfarin drug information.
- ACC: Anticoagulant-related bleeding guidance.
Educational resource: anticoagulation prescribing, interruptions and reversal require current local protocols and senior clinical supervision.
